Training Logbook
Aligned to the UEMS-EBDV European Training Requirements. A companion to your national libretto (e.g. Nomos in Italy) — capture once here in seconds, export anywhere. Cases are anonymised descriptors only.
Progress toward UEMS-EBDV minimums
Quick capture seconds, not forms
Tap what you did — AI structures it into the logbook, your CME wallet and the unit cruscotto at once.
Recent entries
| Today | Dermoscopy — pigmented lesion | case mgmt |
| Today | Excision — melanoma, pT1a | surgery |
| Yesterday | Biopsy — inflammatory | biopsy |
| 2 days ago | Phototherapy session | phys. therapy |
CME Wallet
All your ECMEC® credits in one place — from EADV, your national society and any accredited provider — convertible to your national CME total (EACCME/UEMS) and recognised in the US/Canada.
this 3-yr cycle
You're 62% to target, 14 months remaining — comfortably on track.
Credits by source
EADV remains the issuer — we only collect & convert. Links go to EADV to register.
Academic Profile
Your scholarly output kept current automatically — ready for ASN, internal evaluation and grant applications. Paste a DOI and it files itself everywhere.
ASN dossier readiness II fascia
2 of 3 thresholds met — one more well-cited paper closes the gap.
Add output
Pulls metadata from PubMed/Crossref automatically.
Unit Cruscotto
A live read on how the unit and its people are doing — built entirely from staff micro-logs, no patient data, no hospital-IT integration. The monthly report to upper management / Regione is a one-click export of this.
Activity trend (6 months)
Governance KPIs
Trial Portfolio
Every sponsored study on one board — milestones, recruitment, monitoring, budget. Portfolio metadata only; subject-level data stays in the sponsor's EDC.
| Study | Sponsor | Phase | Recruitment | Next monitoring | Deviations | Status |
|---|---|---|---|---|---|---|
| NOVA-DERM-3 psoriasis, IL-23 | Novartis | III | 18 / 20 | 12 Jun | 0 | On track |
| LILY-AD-2 atopic dermatitis | Lilly | II | 7 / 15 | 3 Jun | 1 | Behind |
| HS-REACH hidradenitis | AbbVie | III | 11 / 12 | 24 Jun | 0 | On track |
| MEL-IO-1 melanoma adjuvant | Academic / IIT | II | 9 / 25 | 9 Jul | 0 | Recruiting |
Need sites? horizontal
MEL-IO-1 is behind on recruitment. The network found 3 European units with matching melanoma volume — open Collaboration →
Team & Workload
Equitable visibility of who carries what — from the same activity logs, not surveillance. Individuals see their own detail; the unit sees fair-share aggregates.
Workload distribution (this month)
European Benchmarking
How your unit compares to anonymised peer units across Europe — you see your rank, never a rival's raw numbers. Deeper sharing is always opt-in. Designed so possessiveness becomes a reason to take part, not to hide.
Your position vs European peers anonymised
Filters: region · unit type (clinical-only / university) · size. Your raw data is never exposed to other units.
Collaboration
The system does the matchmaking — you just say yes. Every match carries an obvious, immediate payoff (a paper, a trial, shared workload, a grant you couldn't get alone).
Rare-disease cohort match
Your unit + ES-04 + DE-11 each hold ~40 cases of a rare genodermatosis. Pooled = a publishable European case series.
Recruiting site wanted
MEL-IO-1 (your unit's own study) is behind. 3 EU units match the melanoma profile and have opted in to be contacted.
IHI consortium forming
An IHI Call-13 idea on AI-supported skin-cancer pathways is seeking clinical sites with your profile. Joining = access to non-dilutive funding.
Sponsors & Funding
Every actor needs a profit. Funders get their KPIs delivered; you get non-dilutive money, sites and partners. The platform stays clean — zero patient data, no clinical-decision role — which is what keeps it fundable and trusted.
€2.4bn EU–industry partnership (EFPIA, MedTech Europe…) under Horizon Europe — the single vehicle that combines EU and pharma money. Call 13 expected summer 2026.
EU innovation body + 130-partner network; digital-health funding (Catapult, Innovation Validation Call 2026).
Skin cancer / melanoma sits squarely in the Cancer Mission & Beating Cancer Plan (prevention, early detection). Managed via HaDEA.
European Reference Network for rare skin diseases (56 centres, 20 countries). We complement it — partner & plug-in, don't reinvent.
Why pharma cares
A live, anonymised map of research-active sites = faster multi-centre recruitment, KOL/centre identification, aggregate real-world patterns (never patient-level), and legitimate medical-education spend. Taken cleanly via IHI, with the zero-PHI firewall intact.
CME Vetrina public · generalist
The public front door: one window onto accredited dermatology CME across Europe, for any doctor. We aggregate EADV + national societies, highlight ECMEC® convertibility, and link out to the organiser — we never replace them. Open the standalone public site ↗
About & positioning
A pan-European platform for complex dermatology units — clinical-only and university. The vision for EADV 2026, Vienna.
The pillar model
Training logbook · CME wallet · activity · trial portfolio · academic output · Director cruscotto. Each member's selfish payback feeds these. Delivers full value to a single unit with zero network — solving cold-start.
Benchmarking · collaboration matchmaking · sponsor bridge · the public vetrina. Runs entirely on the vertical layer's exhaust — nobody feeds the network; it's computed from what they fed themselves.
Three design rules
Holds no patient data by design → GDPR-safe everywhere, no ethics-committee path. Only counts & anonymised aggregates.
No integration with hospital systems. Manual capture, paid back in seconds by AI. It's the staff's tool, not IT's surveillance.
Designed for possessiveness (asymmetric visibility, status) and laziness (zero extra work, system-pushed matches). Every actor gets a profit.
Complementary to EADV — not competing
- CME content & e-learning
- Congress & their events calendar
- EuroGuiDerm guidelines
- JEADV publishing · community
- Unit-level operational cruscotto
- Personal CME wallet + UEMS-EBDV logbook + CV/ASN
- Cross-unit benchmarking
- Collaboration matchmaking · the work-layer
EADV publicly calls for European disease registries and runs burden-of-disease advocacy at population level. Our aggregate, zero-PHI unit layer complements both — so EADV is a potential ally/endorser, not a rival. Links out: EADV · UEMS-EBDV · EACCME/ECMEC®.